

Best Antiviral & Antibacterial Molecule R&D Specialists 2023

Located in Germany, SAJO is a research-driven enterprise working to prepare the world for the inevitable pandemic threats of the future. To this end, it has created advanced technology that can quickly and accurately identify compounds with strong antiviral activity. This will equip humanity with the tools it needs to defeat the next century of infectious diseases.

Originally established as a consulting firm focused on infectious disease, SAJO has evolved into an operational business for antiviral drug development. Its core discipline lies in the market of screening for drugs and drug targets for antiviral intervention.

SAJO was founded by Dr. Sabine Breun and Dr. Jörg Baumann, two experienced scientists turned entrepreneurs. They are committed to contributing towards the global effort to fight the infectious diseases that threaten mankind.

The duo started out in basic research in the 1990s, working in US elite programmes related to infectious diseases, particularly viruses. Eventually, they returned to Germany, where they set up their laboratory in a public research facility and used their established knowledge to move into the field of applied science. In order to achieve their goals, Dr. Breun and Dr. Baumann decided to start their own enterprise: SAJO. There, they invented their groundbreaking technology for the efficient identification and isolation of antiviral molecules.

Antivirals will always be in constant demand across the world. There are countless viral pathogens present in the animal kingdom, a significant number of which have the potential to one day overcome the species barrier and infect humans. This has occurred a number of times before, as we have seen with HIV, Influenza, and SARS-CoV-2, and others. In principle, every virus causing disease in humans has an animal origin.

Because of this, experts believe that another pandemic is inevitable. In fact, the virus that will cause it has already been given a name by the World Health Organization: Pathogen X.

With its proprietary technology, SAJO is able to identify molecules with a broad range of strong antiviral activity in a quick and efficient manner. From this, the company will develop an arsenal of antiviral tools to prepare the world for the pandemic caused by Pathogen X.

Whilst it also partners with biotechnology companies, SAJO primarily serves clients in the pharmaceutical industry, who have the assets and expertise to bring a drug to market but have found that many of their pipelines have run dry. SAJO is well-equipped to replenish these.



With a clear vision, SAJO sets itself apart from competitors through its groundbreaking and unique technology, an invention based on many years of experience and research. Over the years, it has worked to improve, modify, and fine-tune this invention to result in a high-end tool with superior efficacy.

Toxicity is a significant challenge faced by companies that carry out drug screening. Any molecule, once identified, must undergo rigorous toxicity testing, making development time-consuming and costly. SAJO's invention features a screening system which not only sieves out any non-functional and weak molecules but also actively excludes toxic molecules. This is a strong competitive advantage for the company since it speeds up the development process significantly.

Currently, SAJO is working to expand its reach by leveraging the media, conferences, and the internet. The SAJO blog, a pro bono project worked on by Dr. Breun and Dr. Baumann, provides a host of concise scientific information related to infectious diseases, pandemics, and climate change, presented in an easy-to-understand way.

The blog, located on the homepage of the SAJO website, has been receiving increased attention, with its annual visitor count now exceeding 800,000. This is due to the public's growing interest in scientific facts related to the pandemic and other hot topics.

In the coming years, SAJO will continue to search for partners, clients, and investors through internet presentation, B2B contacts, and other channels. Any interested individuals, sectors, clients, and companies are welcome to reach out to SAJO if they wish.

For the rest of 2023 and 2024, SAJO will focus on acquiring solid funding to support it in the next decade. In this time, the company will be able to build a large bank of antiviral and antibacterial molecules. These will provide medication to the world for the next century, enabling humans to consistently fight infectious diseases, regardless of re-emerging and new pathogens. In addition to this, it plans to finalise the development of its technology to include antibacterial screening.

As a result of its outstanding work, SAJO has been awarded Best Antiviral & Antibacterial Molecule R&D Specialists in the Healthcare and Pharmaceutical Awards 2023. We congratulate Dr. Breun and Dr. Baumann on this commendable achievement and look forward to seeing how their ambitious plans unfold.

Contact Details
Contact: Dr. Sabine Breun, Dr. Jörg Baumann
Company: SAJO
e-mail: info@sajo-innovation.de Web
Address:
www.sajo-innovation.de

